Literature DB >> 31068294

[Peripheral blood exosomes from patients with multiple myeloma mediate bortezomib resistance in cultured multiple myeloma cells].

Juxian Tang1, Qi Chen1, Feng Zhang2, Wenjun Zhang2, Sirong Duan2, Duan Xiao2.   

Abstract

OBJECTIVE: To investigate the role of exosome in mediating bortezomib (Btz) resistance in multiple myeloma cells in vitro and explore the underlying mechanisms.
METHODS: Peripheral blood samples were collected from 15 patients with multiple myeloma with Btz tolerance, and serum exosomes were isolated by ultracentrifugation and identified with electron microscopy, NTA and Western blotting. In vitro cultured multiple myeloma cells were treated with gradient concentrations of Btz to determine the optimal drug concentration for subsequent experiment. The cells were pretreated with different concentrations of exosomes, and their sensitivity to BTZ was assessed using MTS assay. We searched the exosome database Exocarta and used STRING to generate the network map and the protein interaction graph.
RESULTS: The diameters of the vesicles isolated from the peripheral blood of the patients were mostly below 200 nm with a mean particle size of 153 nm and a mode of 140.1 nm. The results of Western blotting showed that the isolated exosomes expressed the marker proteins CD63, Tsg101 and Alix. In cultured multiple myeloma cells, pretreatment with exosomes resulted in a decreased sensitivity of the cells to bortezomib, and longer treatment durations and higher exosome concentrations consistently enhanced the resistance of the cells to the same Btz concentration. Analysis of the Exocarta database identified human serum exosomal proteins ABCB1, ABCB4, PDCD6IP, and EGFR, among which EGFR served as a network node.
CONCLUSIONS: Exosome within a specific concentration range may serve as a signal carrier to mediate the resistance of multiple myeloma cells to Btz. EGFR likely plays a key role to promote exosome-mediated Btz resistance in myeloma cells.

Entities:  

Keywords:  bortezomib; drug resistance; exosomes; multiple myeloma

Mesh:

Substances:

Year:  2019        PMID: 31068294      PMCID: PMC6743987          DOI: 10.12122/j.issn.1673-4254.2019.04.16

Source DB:  PubMed          Journal:  Nan Fang Yi Ke Da Xue Xue Bao        ISSN: 1673-4254


  30 in total

1.  Intercellular chaperone transmission via exosomes contributes to maintenance of protein homeostasis at the organismal level.

Authors:  Toshihide Takeuchi; Mari Suzuki; Nobuhiro Fujikake; H Akiko Popiel; Hisae Kikuchi; Shiroh Futaki; Keiji Wada; Yoshitaka Nagai
Journal:  Proc Natl Acad Sci U S A       Date:  2015-04-27       Impact factor: 11.205

Review 2.  The key role of extracellular vesicles in the metastatic process.

Authors:  Hongyun Zhao; Abhinav Achreja; Elisabetta Iessi; Mariantonia Logozzi; Davide Mizzoni; Rossella Di Raimo; Deepak Nagrath; Stefano Fais
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2017-11-24       Impact factor: 10.680

3.  Reduced response of IRE1α/Xbp-1 signaling pathway to bortezomib contributes to drug resistance in multiple myeloma cells.

Authors:  Xiaoxuan Xu; Junru Liu; Beihui Huang; Meilan Chen; Shiwen Yuan; Xiaozhe Li; Juan Li
Journal:  Tumori       Date:  2016-09-07       Impact factor: 2.098

4.  Proteasome inhibitors in cancer therapy: a novel approach to a ubiquitous problem.

Authors:  Kristin R Landis-Piwowar
Journal:  Clin Lab Sci       Date:  2012

5.  Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells.

Authors:  Hadi Valadi; Karin Ekström; Apostolos Bossios; Margareta Sjöstrand; James J Lee; Jan O Lötvall
Journal:  Nat Cell Biol       Date:  2007-05-07       Impact factor: 28.824

6.  TrxR1 inhibition overcomes both hypoxia-induced and acquired bortezomib resistance in multiple myeloma through NF-кβ inhibition.

Authors:  Prahlad V Raninga; Giovanna Di Trapani; Slavica Vuckovic; Kathryn F Tonissen
Journal:  Cell Cycle       Date:  2016       Impact factor: 4.534

7.  Targeting ABCB1 and ABCC1 with their Specific Inhibitor CBT-1® can Overcome Drug Resistance in Osteosarcoma.

Authors:  Marilù Fanelli; Claudia Maria Hattinger; Serena Vella; Elisa Tavanti; Francesca Michelacci; Beth Gudeman; Daryl Barnett; Piero Picci; Massimo Serra
Journal:  Curr Cancer Drug Targets       Date:  2016       Impact factor: 3.428

8.  Transgenic mouse model expressing P53(R172H), luciferase, EGFP, and KRAS(G12D) in a single open reading frame for live imaging of tumor.

Authors:  Hye-Lim Ju; Diego F Calvisi; Hyuk Moon; Sinhwa Baek; Silvia Ribback; Frank Dombrowski; Kyung Joo Cho; Sook In Chung; Kwang-Hyub Han; Simon Weonsang Ro
Journal:  Sci Rep       Date:  2015-01-27       Impact factor: 4.379

9.  Exosomal proteins as prognostic biomarkers in non-small cell lung cancer.

Authors:  B Sandfeld-Paulsen; N Aggerholm-Pedersen; R Bæk; K R Jakobsen; P Meldgaard; B H Folkersen; T R Rasmussen; K Varming; M M Jørgensen; B S Sorensen
Journal:  Mol Oncol       Date:  2016-10-21       Impact factor: 6.603

10.  Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors.

Authors:  Yong Jia; Cai-Hong Yun; Eunyoung Park; Dalia Ercan; Mari Manuia; Jose Juarez; Chunxiao Xu; Kevin Rhee; Ting Chen; Haikuo Zhang; Sangeetha Palakurthi; Jaebong Jang; Gerald Lelais; Michael DiDonato; Badry Bursulaya; Pierre-Yves Michellys; Robert Epple; Thomas H Marsilje; Matthew McNeill; Wenshuo Lu; Jennifer Harris; Steven Bender; Kwok-Kin Wong; Pasi A Jänne; Michael J Eck
Journal:  Nature       Date:  2016-05-25       Impact factor: 49.962

View more
  1 in total

1.  Exosomal miR-487a derived from m2 macrophage promotes the progression of gastric cancer.

Authors:  Xuefeng Yang; Shuang Cai; Yue Shu; Xun Deng; Yuanwei Zhang; Nian He; Lei Wan; Xu Chen; Yan Qu; Shouyang Yu
Journal:  Cell Cycle       Date:  2021-01-31       Impact factor: 4.534

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.